(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
Hosted on MSN5d
FDA Clears Spravato For Monotherapy Depression TreatmentsThe Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...
New Brunswick, NJ January 21, 2025 Johnson & Johnson ( NYSE:JNJ) has finally got its breakthrough depression treatment, ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback